Glad to hear that Gammagard appears to be working for your mother-in-law. As I just posted on the other board, if IVIG pans out as a treatment for AD, it will be one of the biggest stories in the history of the drug/biotech industry. Regards, Dew
from Goldman Sachs 33rd Annual Global Healthcare Conference June 7, 2012
CW: ....we acquired the assets of Virdante around basically biobetters, modifying the Fc region of antibodies to allow us to actually change how they behave and inflammatory properties. So that actually opens a door – another door for us in the new drug front. So it’s pretty exciting.
.... equally excited this technology that we are able to bring in from Virdante, that, I will tell you quick story and that we were actually – weren’t looking at buying the assets of Virdante, we were looking for trying to get access to the IP they had around violation because we were doing our own engineering work on biobetters. And the company didn’t get funded, so we had a chance to buy all the assets of the company. And so we were able to bring it on the development portfolio as well. And that gives us something where should it work, should we actually be able to get this really to work effectively, we have a very direct path to the clinic in a very large product, so that’s really exciting for us, IVIG and sialylated FCB (ph), and some offerings in something that is already partly through, that hopefully clinical set of activity. It’s one of those products where kind of sleeping now but as the research plays out over the next year, year and a half, it could be one of the biggest growth drivers for the company. And so there is a lot in research that I could talk about, I won’t go into it now but at some point, I will probably do, try to bring investors again talk more deeply about our research. There’s a lot going on in the company.
Market Data 
Markets 
AI
